Patients who need PCSK9 inhibitors can’t get them April 29, 2017By Tracey WalkerStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia. Game-changing cholesterol-buster further reduces heart attack, stroke April 16, 2017By Tracey WalkerA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%. PCSK9 Inhibitors: The First of Their KindThe first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents. Four innovative models rein in pharma costs December 05, 2016By Mari EdlinPlans and PBMs are finding new ways to rein in pharmacy costs. Study: New cholesterol drugs cost 356 times more than generics September 29, 2016By Tracey WalkerA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options. Are PCSK9 inhibitors too pricey? August 19, 2016By Christine BlankPCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study. Cardiovascular drugs: Current spending, future outlook May 06, 2016By Tracey WalkerCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population. PCSK9 inhibitor benefits patients with statin intolerance April 08, 2016By Tracey WalkerPCSK9 inhibitor benefits patients with statin intolerance Best candidates for PCSK9 inhibitors February 04, 2016By Mari EdlinPBMs, insurers use cautious approach when managing these cholesterol-lowering drugs. Top ways you can impact drug spending February 03, 2016By Marc O’ConnorHow at-risk negotiations with pharmaceutical manufacturers and medication adherence programs improve both sides of the healthcare value equation: patient outcomes and costs.